Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06507956
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Physical Activity Profile and Sedentary Behaviour in Adults with Cystic Fibrosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Physical Activity Profile and Sedentary Behaviour in Adults with Cystic Fibrosis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACTIVMUCO
Brief Summary:
Cystic fibrosis is a multisystem genetic disease whose severity linked to the nature of the mutation in the gene carried is linked to respiratory impairment which determines the vital prognosis
Considerable progress has been made in the management of this disease amplified in recent years by the arrival of CFTR cystic fibrosis transmembrane conductance regulator modulator drugs and in particular the triple treatment combination of elexacaftor-tezacaftor-ivacaftor ETI This modulator therapy improves clinical condition particularly respiratory and transforms quality of life and prognosis for some patients Faced with this clinical improvement practices and care paths are adapting Professionals will have to cope with the emergence of new clinical conditions linked to the ageing of this at-risk population and the functional decline due to a sedentary lifestyle and age
The working hypothesis is that a better understanding of the physical activity and sedentary lifestyle profiles of the adult population with cystic fibrosis and in particular the characterization of the profile of inactive and high sedentary patients under ETI will enable us to identify and target patients whose lifestyle habits reflect a greater health risk and for whom care by rehabilitators and adapted physical activity APA teachers and personalized advice could be put in place
The aim of this study is to characterize the physical activity and sedentary profile of adults with cystic fibrosis
ACTIVMUCO is an observational cross-sectional single-center study A subgroup of adults with high sedentary and inactive under ETI will be studied more specifically by actimetry prospective follow-up and interview
Considerable progress has been made in the management of this disease amplified in recent years by the arrival of CFTR cystic fibrosis transmembrane conductance regulator modulator drugs and in particular the triple treatment combination of elexacaftor-tezacaftor-ivacaftor ETI This modulator therapy improves clinical condition particularly respiratory and transforms quality of life and prognosis for some patients Faced with this clinical improvement practices and care paths are adapting Professionals will have to cope with the emergence of new clinical conditions linked to the ageing of this at-risk population and the functional decline due to a sedentary lifestyle and age
The working hypothesis is that a better understanding of the physical activity and sedentary lifestyle profiles of the adult population with cystic fibrosis and in particular the characterization of the profile of inactive and high sedentary patients under ETI will enable us to identify and target patients whose lifestyle habits reflect a greater health risk and for whom care by rehabilitators and adapted physical activity APA teachers and personalized advice could be put in place
The aim of this study is to characterize the physical activity and sedentary profile of adults with cystic fibrosis
ACTIVMUCO is an observational cross-sectional single-center study A subgroup of adults with high sedentary and inactive under ETI will be studied more specifically by actimetry prospective follow-up and interview
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None